MXPA02002579A - Entrega de liposomas cationicas de taxanos a vasos sanguineos angiogenicos. - Google Patents

Entrega de liposomas cationicas de taxanos a vasos sanguineos angiogenicos.

Info

Publication number
MXPA02002579A
MXPA02002579A MXPA02002579A MXPA02002579A MXPA02002579A MX PA02002579 A MXPA02002579 A MX PA02002579A MX PA02002579 A MXPA02002579 A MX PA02002579A MX PA02002579 A MXPA02002579 A MX PA02002579A MX PA02002579 A MXPA02002579 A MX PA02002579A
Authority
MX
Mexico
Prior art keywords
taxanes
blood vessels
cationic liposome
liposome delivery
angiogenic blood
Prior art date
Application number
MXPA02002579A
Other languages
English (en)
Inventor
Donald M Mcdonald
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Publication of MXPA02002579A publication Critical patent/MXPA02002579A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
MXPA02002579A 1999-09-09 2000-09-08 Entrega de liposomas cationicas de taxanos a vasos sanguineos angiogenicos. MXPA02002579A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39297699A 1999-09-09 1999-09-09
PCT/US2000/024579 WO2001017508A1 (en) 1999-09-09 2000-09-08 Cationic liposome delivery of taxanes to angiogenic blood vessels

Publications (1)

Publication Number Publication Date
MXPA02002579A true MXPA02002579A (es) 2003-10-14

Family

ID=23552795

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA02002579A MXPA02002579A (es) 1999-09-09 2000-09-08 Entrega de liposomas cationicas de taxanos a vasos sanguineos angiogenicos.

Country Status (21)

Country Link
US (1) US20100226970A1 (es)
EP (1) EP1210065B1 (es)
JP (2) JP4848113B2 (es)
KR (1) KR100591767B1 (es)
CN (1) CN1235567C (es)
AT (1) ATE324867T1 (es)
AU (1) AU782714B2 (es)
BR (1) BR0013866A (es)
CA (1) CA2383412C (es)
CZ (1) CZ2002850A3 (es)
DE (1) DE60027730T2 (es)
EA (1) EA005923B1 (es)
EE (1) EE200200127A (es)
ES (1) ES2258471T3 (es)
HK (1) HK1046506B (es)
HU (1) HUP0202669A3 (es)
IL (2) IL148372A0 (es)
MX (1) MXPA02002579A (es)
PL (1) PL203128B1 (es)
WO (1) WO2001017508A1 (es)
ZA (1) ZA200201555B (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ20023913A3 (cs) * 2000-05-03 2003-09-17 Munich Biotech Ag Kationtová diagnostická, zobrazovací a terapeutická činidla spojená s aktivovanými cévními místy
WO2003028696A2 (en) * 2001-10-03 2003-04-10 Celator Technologies Inc. Compositions for delivery of drug combinations
CA2383259A1 (en) 2002-04-23 2003-10-23 Celator Technologies Inc. Synergistic compositions
US7850990B2 (en) 2001-10-03 2010-12-14 Celator Pharmaceuticals, Inc. Compositions for delivery of drug combinations
WO2003099346A2 (en) 2002-05-24 2003-12-04 Angiotech International Ag Compositions and methods for coating medical implants
EP1374864A1 (en) * 2002-06-26 2004-01-02 Munich Biotech AG Amphiphilic taxane compositions
CA2492080A1 (en) * 2002-06-26 2004-01-08 Medigene Oncology Gmbh Novel method of stabilizing diagnostic and therapeutic compounds in a cationic carrier system
EP2277507A1 (en) * 2002-06-26 2011-01-26 MediGene AG Method of producing a cationic liposomal preparation comprising a lipophilic compound
US8986736B2 (en) 2003-06-24 2015-03-24 Baxter International Inc. Method for delivering particulate drugs to tissues
WO2004112747A2 (en) 2003-06-24 2004-12-29 Baxter International Inc. Specific delivery of drugs to the brain
JP5645340B2 (ja) * 2003-10-15 2014-12-24 メディゲーネ アクチエンゲゼルシャフトＭｅｄｉＧｅｎｅ ＡＧ 活性成分を含有するカチオンリポソームの投与方法
US7803374B2 (en) 2004-01-16 2010-09-28 Barnes-Jewish Hospital Targeted atherosclerosis treatment
CA2601067A1 (en) * 2005-05-04 2006-11-09 Medigene Ag Method of administering a cationic liposomal preparation comprising paclitaxel
CA2922029C (en) 2006-03-22 2017-11-28 Medigene Ag A combination of a cationic liposomal preparation comprising an antimitotic agent and a non-liposomal preparation comprising an antimitotic agent
CN101965195A (zh) 2008-03-05 2011-02-02 巴克斯特国际公司 用于药物投送的组合物和方法
US10952965B2 (en) 2009-05-15 2021-03-23 Baxter International Inc. Compositions and methods for drug delivery
US9706903B2 (en) 2009-06-18 2017-07-18 Endochoice, Inc. Multiple viewing elements endoscope system with modular imaging units
DE102009032658A1 (de) * 2009-07-09 2011-01-13 Forschungszentrum Jülich GmbH Mischung amphipathischer Moleküle und Verfahren zur Zellmembranmodifikation durch Fusion
KR101007925B1 (ko) * 2009-10-07 2011-01-14 건일제약 주식회사 경구용 지질 나노입자 및 그의 제조방법
EP3532067B1 (en) * 2016-10-28 2022-05-04 Les Laboratoires Servier Liposomal formulation for use in the treatment of cancer
KR102250123B1 (ko) 2019-11-25 2021-05-10 주식회사 현대케피코 무단 변속기의 제한 목표 기어비 학습 방법
KR102261482B1 (ko) 2019-12-10 2021-06-07 주식회사 현대케피코 무단 변속기의 킥다운 시프트 직후 구동 풀리 제어 압력 보정 방법 및 장치

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4394448A (en) * 1978-02-24 1983-07-19 Szoka Jr Francis C Method of inserting DNA into living cells
US4897355A (en) * 1985-01-07 1990-01-30 Syntex (U.S.A.) Inc. N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US5092885A (en) * 1987-02-12 1992-03-03 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Peptides with laminin activity
US5110730A (en) * 1987-03-31 1992-05-05 The Scripps Research Institute Human tissue factor related DNA segments
US5328470A (en) * 1989-03-31 1994-07-12 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
US5192744A (en) * 1990-01-12 1993-03-09 Northwestern University Method of inhibiting angiogenesis of tumors
US5264618A (en) * 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
EP0470569B1 (en) * 1990-08-08 1995-11-22 Takeda Chemical Industries, Ltd. Intravascular embolizing agent containing angiogenesis inhibiting substance
US6605712B1 (en) * 1990-12-20 2003-08-12 Arch Development Corporation Gene transcription and ionizing radiation: methods and compositions
WO1993018751A1 (en) * 1992-03-23 1993-09-30 Georgetown University Liposome encapsulated taxol and a method of using the same
US6096331A (en) * 1993-02-22 2000-08-01 Vivorx Pharmaceuticals, Inc. Methods and compositions useful for administration of chemotherapeutic agents
AU6833994A (en) * 1993-05-17 1994-12-12 Liposome Company, Inc., The Incorporation of taxol into liposomes and gels
CA2161328A1 (en) * 1993-06-11 1994-12-22 Robert C. Kelly Delta 6,7-taxols antineoplastic use and pharmaceutical compositions containing them
EP1118325B2 (en) * 1993-07-29 2010-01-06 The United States of America, represented by the Secretary, Department of Health and Human Services Use of Paclitaxel and its derivatives in the manufacture of a medicament for treating restenosis.
US5415869A (en) * 1993-11-12 1995-05-16 The Research Foundation Of State University Of New York Taxol formulation
US5641755A (en) * 1994-02-04 1997-06-24 Arch Development Corp. Regulation of x-ray mediated gene expression
US5837682A (en) * 1996-03-08 1998-11-17 The Children's Medical Center Corporation Angiostatin fragments and method of use
US5512294A (en) * 1994-08-05 1996-04-30 Li; King C. Targeted polymerized liposome contrast agents
GB9506466D0 (en) * 1994-08-26 1995-05-17 Prolifix Ltd Cell cycle regulated repressor and dna element
US5580899A (en) * 1995-01-09 1996-12-03 The Liposome Company, Inc. Hydrophobic taxane derivatives
DE19605274A1 (de) * 1996-02-13 1997-08-14 Hoechst Ag Nukleinsäurekonstrukte für die zellzyklusregulierte Expression von Genen, derartige Konstrukte enthaltende Zellen sowie deren Verwendung zur Herstellung von Heilmitteln
PT932399E (pt) * 1996-03-12 2006-05-31 Pg Txl Co Lp Pro-farmacos de paclitaxel hidrossoluveis
US5935937A (en) * 1996-06-19 1999-08-10 Fox Chase Cancer Center Compositions and methods for inducing apoptosis
US7112338B2 (en) * 1997-03-12 2006-09-26 The Regents Of The University Of California Cationic liposome delivery of taxanes to angiogenic blood vessels
US5837283A (en) * 1997-03-12 1998-11-17 The Regents Of The University Of California Cationic lipid compositions targeting angiogenic endothelial cells
US6146659A (en) * 1998-07-01 2000-11-14 Neopharm, Inc. Method of administering liposomal encapsulated taxane
WO2000047235A2 (en) * 1999-02-10 2000-08-17 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of stimulating angiogenesis
DE60238780D1 (de) * 2001-10-30 2011-02-10 Novartis Ag Depot formulierungen von iloperidone und einem sternförmigen polymer

Also Published As

Publication number Publication date
KR100591767B1 (ko) 2006-06-23
CN1378443A (zh) 2002-11-06
EP1210065B1 (en) 2006-05-03
HK1046506A1 (en) 2003-01-17
ZA200201555B (en) 2003-04-30
CN1235567C (zh) 2006-01-11
PL203128B1 (pl) 2009-08-31
AU782714B2 (en) 2005-08-25
KR20030038530A (ko) 2003-05-16
CZ2002850A3 (cs) 2003-04-16
CA2383412A1 (en) 2001-03-15
EE200200127A (et) 2003-04-15
BR0013866A (pt) 2002-05-14
PL354721A1 (en) 2004-02-09
JP2003514768A (ja) 2003-04-22
US20100226970A1 (en) 2010-09-09
EA005923B1 (ru) 2005-08-25
EA200200229A1 (ru) 2003-06-26
ATE324867T1 (de) 2006-06-15
EP1210065A4 (en) 2004-04-28
WO2001017508A1 (en) 2001-03-15
HK1046506B (zh) 2006-08-25
JP4848113B2 (ja) 2011-12-28
CA2383412C (en) 2010-02-02
ES2258471T3 (es) 2006-09-01
DE60027730D1 (de) 2006-06-08
HUP0202669A3 (en) 2004-06-28
JP2010280667A (ja) 2010-12-16
IL148372A0 (en) 2002-09-12
DE60027730T2 (de) 2007-03-29
WO2001017508A9 (en) 2002-10-03
AU7122900A (en) 2001-04-10
HUP0202669A2 (hu) 2004-05-28
IL148372A (en) 2007-09-20
EP1210065A1 (en) 2002-06-05

Similar Documents

Publication Publication Date Title
HK1046506A1 (en) Cationic liposome delivery of taxanes to angiogenic blood vessels
IL171355A (en) Cationic lipid compositions targeting angiogenic endothelial cells
EP1846014B1 (en) Selective delivery of molecules into cells or marking of cells in diseased tissue regions using environmentally sensitive transmembrane peptide
Gibot et al. Antitumor drug delivery in multicellular spheroids by electropermeabilization
DE69708919T2 (de) Neue liposomkomplexe mit erhöhter systemischer verabreichung
Sugahara et al. The cytotoxic effect of Eucheuma serra agglutinin (ESA) on cancer cells and its application to molecular probe for drug delivery system using lipid vesicles
ATE462468T1 (de) Vorrichtungen zur vergrösserten penetration von mikronadeln in biologischen hautschichten
DE69730218D1 (de) Fusogene liposomen
WO2005051351A3 (en) Gene delivery mediated by liposome-dna complex with cleavable peg surface modification
WO1999048536A3 (en) Delivery of long lasting therapeutic agents by forming covalent attachments in vivo
MX9801264A (es) Control de la expresion del gen de cd44 para uso terapeutico.
AU2002217760A1 (en) Targeting drug/gene carriers to irradiated tissue
WO2004113497A3 (en) Gene delivery to tumors
ATE419833T1 (de) Modulares zielgerichtetes liposomales verabreichungssytem
CN203360445U (zh) 超声微泡介导转染辅助装置
Shinkai et al. Silencing of BCR/ABL chimeric gene in human chronic myelogenous leukemia cell line K562 by siRNA-nuclear export signal peptide conjugates
NZ516777A (en) Method for delivery of therapeutic agents, particularly nucleic acids, using a solution of dextrin
ATE368027T1 (de) Bipolare lipide und ihre verwendung zum transport bioaktiver substanzen
Pike et al. Genetic jottings
IT246835Y1 (it) Struttura di supporto per contenitori particolarmente di prodotti incarta , in foglio e simili
Straubinger LIPOSOME-CELL INTERACTION: MECHANISM OF LIPOSOME INTERNALIZATION AND INTRACELLULAR FATE OF LIPOSOME CONTENTS (ENDOCYTOSIS, DRUG CARRIER, CANCER CHEMOTHERAPY, MICROINJECTION, TRANSFECTION SYSTEM)
TH33765A (th) ตัวกระตุ้นฤทธิ์เอนไซม์นิวคลีเอสของเซลล์มะเร็ง

Legal Events

Date Code Title Description
FG Grant or registration